Current Therapeutic Research-clinical and Experimental最新文献

{"title":"Effectiveness of Netarsudil versus Brimonidine in Eyes already Being Treated with Glaucoma Medications at a Single Academic Tertiary Care Practice: A Comparative Study","authors":"Alex T. Pham BS ,&nbsp;Chris Bradley PhD ,&nbsp;Corinne Casey OD ,&nbsp;Henry D. Jampel MD ,&nbsp;Pradeep Y. Ramulu MD, PhD ,&nbsp;Jithin Yohannan MD, MPH","doi":"10.1016/j.curtheres.2022.100689","DOIUrl":"10.1016/j.curtheres.2022.100689","url":null,"abstract":"<div><h3>Background</h3><p>Rho kinase inhibitors, such as netarsudil, are a relatively new class of medications recently introduced into the market for the treatment of glaucoma, the leading cause of irreversible blindness in the world. Previous clinical trials have studied netarsudil's efficacy when used as a first- or second-line agent but limited studies have investigated its effectiveness in the real world where it is more commonly used as a third, fourth, or fifth agent in combination with other topical medications. Equally important, prior studies have not compared its effectiveness to its peer medications in these settings.</p></div><div><h3>Objective</h3><p>To compare intraocular pressure (IOP) lowering after initiation of netarsudil or brimonidine therapy in patients with glaucoma using &gt;2 medications for IOP management.</p></div><div><h3>Methods</h3><p>A chart review of 369 eyes from 279 patients followed at a single academic tertiary practice was performed with an institutional review board waiver of consent to compare IOP lowering after prescription of netarsudil (n = 176) versus brimonidine (n = 193) as a third, fourth, or fifth IOP-lowering agent. Patients were identified by querying the electronic medical record for those with a glaucoma-related diagnosis who were prescribed either medication. Five sequential IOP measurements were obtained to determine the mean change in IOP before and after treatment (ΔIOP = mean IOP_4,5 – mean IOP_1,2,3). A multilevel linear mixed-effects model assessed the influence of medication (independent variable) on ΔIOP (dependent variable). Additional independent variables of interest included the number of glaucoma medications at baseline, age, sex, glaucoma type and severity, race, and pretreatment IOP. Bootstrap analysis was performed to remove sampling bias and confirm mixed-effects model findings. Kaplan-Meier survival analysis evaluated the probability of requiring additional intervention within 3 years following the date of medication prescription.</p></div><div><h3>Results</h3><p>The unadjusted mean (SD) ΔIOP for netarsudil and brimonidine was −2.20 (4.11) mm Hg and −2.21 (3.25) mm Hg, respectively (<em>P</em> = 0.484). The adjusted linear mixed-effects models and bootstrap analysis demonstrated that there was no statistical difference in IOP-lowering effectiveness between the medications. Netarsudil and brimonidine failed to adequately control IOP at similar rates with 42% and 47% probabilities of survival respectively by the 3-year follow-up (<em>P</em> = 0.520).</p></div><div><h3>Conclusions</h3><p>When escalating pharmacologic therapy, the IOP-lowering effect of netarsudil appeared to be similar to that produced by brimonidine. (<em>Curr Ther Res Clin Exp</em>. 2023; 84:XXX–XXX)</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"98 ","pages":"Article 100689"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/76/main.PMC9792385.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Acceptance and Commitment Therapy Smartphone Application for Erectile Dysfunction: A Feasibility Study","authors":"Junichi Saito PhD ,&nbsp;Hiroaki Kumano MD, PhD ,&nbsp;Mohammad Ghazizadeh MD, PhD ,&nbsp;Chigusa Shimokawa ,&nbsp;Hideki Tanemura","doi":"10.1016/j.curtheres.2023.100728","DOIUrl":"https://doi.org/10.1016/j.curtheres.2023.100728","url":null,"abstract":"<div><h3>Background</h3><p>Erectile dysfunction (ED) is a multifactorial disorder with both psychogenic and organic components, but psychosocial factors are usually neglected.</p></div><div><h3>Objective</h3><p>The purpose of this study was to develop a smartphone application targeting psychosocial factors of ED and to examine its feasibility, acceptability, and treatment response to determine the parameters for a larger clinical trial.</p></div><div><h3>Methods</h3><p>In this single-arm feasibility study, 8 participants with situational ED were enrolled. Dr. App, a newly developed smartphone treatment application for patients with psychogenic ED consisting of 8 weekly modules based on Acceptance and Commitment Therapy, was delivered. The primary outcome was comparison of the International Index of Erectile Function-15 domain scores measured pre- and post-intervention.</p></div><div><h3>Results</h3><p>Six out of 8 participants completed the Dr. App and the post-intervention measures. The Wilcoxon signed-rank test showed a significant change in erectile function (<em>P</em> &lt; 0.05; <em>r</em> = –0.65) and a significant trend in intercourse satisfaction (<em>P</em> &lt; 0.10; <em>r</em> = –0.47) and overall satisfaction (<em>P</em> &lt; .10; <em>r</em> = –0.47). Additionally, the reliable change index values were used to calculate the number of participants for whom a clinically meaningful difference occurred. The results showed that 33.30% of the participants had clinically meaningful differences in erectile function and 66.70% in intercourse satisfaction and overall satisfaction. On the other hand, no significant differences were shown in orgasmic function and sexual desire.</p></div><div><h3>Conclusions</h3><p>Findings from this study support the feasibility, acceptability, and potential usefulness of the smartphone application targeting psychosocial factors of ED and warrant a larger randomized clinical trial to confirm the results.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"99 ","pages":"Article 100728"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X23000371/pdfft?md5=c3bcdc21066f10ae8b4dab662be3e326&pid=1-s2.0-S0011393X23000371-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138484382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review","authors":"Silvia Joseph, Steffie Maria, J. Peedicayil","doi":"10.1016/j.curtheres.2022.100669","DOIUrl":"https://doi.org/10.1016/j.curtheres.2022.100669","url":null,"abstract":"","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"156 5 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75609495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoformulation of Plant-Based Natural Products for Type 2 Diabetes Mellitus: From Formulation Design to Therapeutic Applications","authors":"A. Wickramasinghe, P. Kalansuriya, A. Attanayake","doi":"10.1016/j.curtheres.2022.100672","DOIUrl":"https://doi.org/10.1016/j.curtheres.2022.100672","url":null,"abstract":"","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"25 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74780416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Ramosetron on Nausea and Vomiting Following Spinal Surgery: A Meta-Analysis","authors":"Lin Yiyun, Su Tiansheng, Zhang Zhicheng, C. Xiaobin, L. Fang","doi":"10.1016/j.curtheres.2022.100666","DOIUrl":"https://doi.org/10.1016/j.curtheres.2022.100666","url":null,"abstract":"","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"1 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78413543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Area Under the Concentration-Time Curve-Guided Monitoring on Vancomycin Nephrotoxicity and Treatment Outcomes in Methicillin-Resistant Staphylococcus Aureus Bacteremia in Korean Patients","authors":"Young Rong Kim MD ,&nbsp;Ha-Jin Chun ,&nbsp;Jung Yeon Heo MD, PhD ,&nbsp;Jin Sae Yoo MD ,&nbsp;Young Hwa Choi MD, PhD ,&nbsp;Eun Jin Kim MD","doi":"10.1016/j.curtheres.2022.100687","DOIUrl":"10.1016/j.curtheres.2022.100687","url":null,"abstract":"<div><h3>Background</h3><p>Current guidelines for the therapeutic monitoring of vancomycin recommend dosing based on the area under the concentration-time curve (AUC) to achieve clinical efficacy while reducing nephrotoxicity. Although a wide range of nephrotoxicity thresholds have been reported, few studies have documented clinical outcomes based on AUC-guided vancomycin dosing in Korea.</p></div><div><h3>Objective</h3><p>The aim of the study was to evaluate whether a relationship exists between AUC and treatment outcomes in vancomycin treated patients in methicillin-resistant <em>Staphylococcus aureus</em> bacteremia. Furthermore, this study tries to estimate AUC threshold for treatment failure and nephrotoxicity.</p></div><div><h3>Methods</h3><p>The records of adult patients with methicillin-resistant <em>Staphylococcus aureus</em> bacteremia treated with vancomycin for ≥72 hours without dialysis between April 2013 and April 2021, were reviewed retrospectively. Treatment success was defined as defervescence and blood culture sterilization by day 7. Nephrotoxicity was defined as an increase in serum creatinine levels ≥0.3 mg/dL or a 50% increase from baseline on 2 consecutive days. Bayesian estimation was used to predict individual vancomycin AUC. Both classification and regression tree and receiver operating characteristic curve analyses were performed to estimate the optimal AUC thresholds for vancomycin efficacy and nephrotoxicity.</p></div><div><h3>Results</h3><p>Of 118 patients, 61 (51.7%) experienced treatment failure and 42 (35.6%) developed acute kidney injury. The vancomycin AUC threshold for predicting acute kidney injury was 615.0 mg· hr/L. In the multivariate analysis, AUC ≥615.0 mg· hr/L was a significant risk factor for nephrotoxicity (adjusted odds ratio [aOR] = 5.24; 95% CI, 1.8–14.65). The lower threshold for treatment failure was not defined because it was not statistically significant. Risk factors for treatment failure included low body mass index (aOR = 0.82; 95% CI, 0.70–0.96), severity of acute illness represented by complicated infection (aOR = 77.56; 95% CI, 16.7–359.4) and comorbidities, such as solid organ tumors (aOR = 6.61; 95% CI, 1.19–36.81) and cerebrovascular disease (aOR = 6.05; 95% CI, 1.17–31.23).</p></div><div><h3>Conclusions</h3><p>Although AUC-guided vancomycin dosing was associated with a reduced risk of acute kidney injury, its ability to predict clinical outcomes was modest. Further studies are needed to define the AUC therapeutic range to maximize efficacy and minimize nephrotoxicity. (<em>Curr Ther Res Clin Exp.</em> 2023; 83:XXX–XXX)</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"97 ","pages":"Article 100687"},"PeriodicalIF":1.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/55/main.PMC9691871.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40499698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem Cell Therapy for Thyroid Diseases: Progress and Challenges","authors":"Sunyi Ye Ph.D.,&nbsp;Zhu Lixian M.D.","doi":"10.1016/j.curtheres.2022.100665","DOIUrl":"10.1016/j.curtheres.2022.100665","url":null,"abstract":"<div><h3>Background</h3><p>Thyroid hormones are indispensable for organ development and maintaining homeostasis. Thyroid diseases, including thyroiditis and thyroid cancer, affect the normal secretion of hormones and result in thyroid dysfunction.</p></div><div><h3>Objective</h3><p>This review focuses on therapeutic applications of stem cells for thyroid diseases.</p></div><div><h3>Methods</h3><p>A literature search of Medline and PubMed was conducted (January 2000–July 2021) to identify recent reports on stem cell therapy for thyroid diseases.</p></div><div><h3>Results</h3><p>Stem cells are partially developed cell types. They have the capacity to form specialized cells. Besides embryonic stem cells and mesenchymal stem cells, organ resident stem cells and cancer stem cells are recently reported to have important roles in forming organ specific cells and cancers. Stem cells, especially mesenchymal stem cells, have anti-inflammatory and anticancer functions as well.</p></div><div><h3>Conclusions</h3><p>This review outlines the therapeutic potency of embryonic stem cells, mesenchymal stem cells, thyroid resident stem cells, and thyroid cancer stem cells in thyroid cells’ regeneration, thyroid function modulation, thyroiditis suppression, and antithyroid cancers. Stem cells represent a promising form of treatment for thyroid disorders.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"96 ","pages":"Article 100665"},"PeriodicalIF":1.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X22000042/pdfft?md5=208dfa39f4c1828008254b6169fd0adb&pid=1-s2.0-S0011393X22000042-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54106412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ``Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats'' [Current Therapeutic Research Volume 95, 2021, 100647]","authors":"Mohammed Fouad Shalaby ,&nbsp;Hekma A. Abd El Latif ,&nbsp;Mohamed El Yamani ,&nbsp;May Ahmed Galal ,&nbsp;Sherifa Kamal ,&nbsp;Ikhlas Sindi","doi":"10.1016/j.curtheres.2022.100664","DOIUrl":"10.1016/j.curtheres.2022.100664","url":null,"abstract":"","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"96 ","pages":"Article 100664"},"PeriodicalIF":1.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/54/main.PMC9846453.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10560430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Benefit of Clinical Research in Diversely Advanced African Developing Countries","authors":"Vanessa Strüver BA, MSc ,&nbsp;Sheraz Ali PharmD, PhD Sch, MPH ,&nbsp;Firas Fneish MSc ,&nbsp;Gerhard Fortwengel BSc, MPH, PhD","doi":"10.1016/j.curtheres.2021.100656","DOIUrl":"10.1016/j.curtheres.2021.100656","url":null,"abstract":"<div><h3>Background</h3><p>The globalization of clinical research should also benefit the population in developing markets. In this context, the approval of tested medicines and the associated expansion of medical care beyond clinical studies would be desirable as a possible long-term benefit.</p></div><div><h3>Objectives</h3><p>This study was designed to compare the development of the number of clinical trials with the number of marketing authorizations of medicines on the African continent. To contrast these 2 parameters, the data were analyzed using the model of an ecological study.</p></div><div><h3>Methods</h3><p>To reflect the broad spectrum of African developing countries with diverse levels of development, the data collection was based on 2 geographically selected sample countries each from Central, North, East, West, and Southern Africa. Based on the ClinicalTrials.gov registry, the first step was to collect trends data on the development of the clinical trials in the 10 selected countries of the country list of the African Region published by the World Health Organization for the period 2015 to 2018. Subsequently, data on the current number of marketing authorizations of medicines in the selected sample countries were identified using the online registries of the national authorities. The data were utilized in comparative analyses.</p></div><div><h3>Results</h3><p>Eight out of 10 model countries showed an increase in the number of clinical trials, with the exceptions of Cameroon and Libya, which showed an overall decline in research activity over the entire time. In direct comparison with drug registrations, the numbers indicate a similar development. The only exception here is Nigeria, a country with a solid performance in clinical research and yet a decrease in medicine registrations since 2015.</p></div><div><h3>Conclusions</h3><p>The expected increase in the development of clinical research as result of the globalization trend can basically be observed in most of the model countries. However, this increase does not guarantee an improvement in the number of medicine registrations. Although this is evident in some of the selected model countries, it cannot be projected to the entire African region. This may be linked to the diverse development of the individual countries due to the different political situations and the varying degrees of clinical research infrastructure. (<em>Curr Ther Res Clin Exp</em>. 2022; 82:XXX–XXX)</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"96 ","pages":"Article 100656"},"PeriodicalIF":1.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d5/bd/main.PMC8688875.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39779314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Post-Marketing Surveillance Study to Evaluate the Safety Profile of AlvotereⓇ (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy","authors":"Farhad Shahi Associate Professor ,&nbsp;Farahnaz Vafaeezadeh Post doctoral fellowship ,&nbsp;Nafiseh Ansarinejad Associate Professor ,&nbsp;Alireza Ahmadi Post doctoral fellowship ,&nbsp;Ali Shahriari-Ahmadi Associate Professor ,&nbsp;Alireza Ghazizadeh Associate Professor ,&nbsp;Hassanali Vahedian Ardakani Associate Professor ,&nbsp;Mohammad Reza Ravanbod Associate Professor ,&nbsp;Sharareh Seifi Associate Professor ,&nbsp;Mohammad Foratyazdi Associate Professor ,&nbsp;Seyed Asadollah Mousavi Associate Professor ,&nbsp;Mansour Rajabi Vahid Associate Professor ,&nbsp;Hossein Rahimi Associate Professor ,&nbsp;Mohammad Seghatoleslami Post doctoral fellowship ,&nbsp;Seyed Mohsen Razavi Associate Professor ,&nbsp;Amir Houshang Pourkhani Associate Professor ,&nbsp;Davoud Babakhani Post doctoral fellowship ,&nbsp;Nassim Anjidani Pharm. D.","doi":"10.1016/j.curtheres.2021.100659","DOIUrl":"10.1016/j.curtheres.2021.100659","url":null,"abstract":"<div><h3>Background</h3><p>Docetaxel is a clinically well established antimitotic chemotherapy medication. Labeled docetaxel indications are breast cancer, gastric cancer, head and neck cancer, non–small cell lung cancer, and prostate cancer.</p></div><div><h3>Objective</h3><p>This is a Phase IV study to evaluate the safety profile of docetaxel (Alvotere; NanoAlvand, Iran) in Iranian patients diagnosed with different types of cancers receiving chemotherapy regimens with docetaxel.</p></div><div><h3>Methods</h3><p>Patients who received Alvotere as a part of their chemotherapy regimen were enrolled in this Phase IV, observational, multicenter, open-label study. Alvotere was administrated as a single agent or in combination with other chemotherapy agents. Safety parameters in each cycle were assessed, and the related data were recorded in booklets.</p></div><div><h3>Findings</h3><p>A total of 411 patients with different types of cancers were enrolled from 25 centers in Iran. The most common malignancies among participants were breast cancer (49.88%), followed by gastric cancer (22.63%). Participants’ mean age was 53.33 years, and the mean total dose used in each cycle was 132 mg. According to the results, 341 patients experienced at least 1 adverse event, that the most common was alopecia (41.12%). In total, 92 (22.38%) patients had at least 1 adverse event of grade 3 or 4, and 25 (6.08%) patients showed 54 serious adverse events, which the causality assessment for all was possibly related to Alvotere. There was a significant difference between men and women in the incidence of skin and subcutaneous tissue disorders (55.63% in women vs 41.73% in men; <em>P</em> = 0.009). Also, the incidence of gastrointestinal disorders, nervous system disorders, skin and subcutaneous tissue disorders, hepatic enzymes increase, and fluid retention was significantly higher (<em>P</em> &lt; 0.05) in patients receiving anthracyclines in their chemotherapy regimens.</p></div><div><h3>Conclusions</h3><p>The findings of this open-label, observational, multicenter, postmarketing surveillance showed that Alvotere appears to have an acceptable safety profile in Iranian cancer patients receiving chemotherapeutic regimens. (<em>Curr Ther Res Clin Exp</em>. 2022; 82:XXX–XXX) © 2022 Elsevier HS Journals, Inc.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"96 ","pages":"Article 100659"},"PeriodicalIF":1.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/92/main.PMC8749121.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39825622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}